Affärsvärlden has issued a neutral recommendation for the life science company Addlife, according to an analysis published on Monday.
The serial acquirer has been forced to slow down its pace of acquisitions in recent years due to a high level of debt. Nevertheless, the stock has performed strongly this year, with a 40 percent increase in share price. Management expects a gradual uptick in acquisition activity going forward, the magazine notes.
"The larger serial acquirers on the stock market are generally valued highly. Addlife does not stand out as cheap and, as mentioned, also carries a fairly high debt load (3.1 times EBITDA). We remain on the sidelines with a neutral recommendation," Affärsvärlden writes.
